Постковидный синдром с позиции ревматолога: проблемы дифференциальной диагностики

Особенностью постковидного синдрома (ПКС) как нозологической единицы является широкий спектр клинических проявлений, что значительно затрудняет его диагностику и делает постановку диагноза возможной лишь после исключения других потенциальных причин. В статье рассматриваются симптомы, которые встречаются как при ПКС, так и при ревматических заболеваниях. Авторы делают акцент на сходстве и различиях клинических проявлений в обоих случаях, а также на методах диагностики и мониторинга, которые встречаются в литературе. Подчеркивается необходимость скрупулезного обследования пациентов с впервые возникшими симптомами для своевременного выявления ревматического заболевания.

1. Rahmati M, Udeh R, Yon DK, et al. A systematic review and meta-analysis of long-term sequelae of COVID-19 2–year after SARS-CoV-2 infection: A call to action for neurological, physical, and psychological sciences. J Med Virol. 2023; 95: e28852. https://doi.org/10.1002/jmv.28852

2. Petersen MS, Kristiansen MF, Hanusson KD. et al. Long COVID in the Faroe Islands – a longitudinal study among non-hospitalized patients. Clin. Infect. Dis. 2021; 73: 11: e4058–e4063. https://doi.org/10.1093/cid/ciaa1792

3. Carvalho-Schneider C, Laurent E, Lemaignen A. et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 2021; 27 (2): 258–263. DOI: 10.1016/j.cmi.2020.09.052

4. Lopez-Leon S, Wegman-Ostrosky T, Perelman C. et al. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci Rep. 2021; 11: 16144. https://doi.org/10.1038/s41598-021-95565-86

5. Ghosn J, Piroth L, Epaulard O. et al. Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort. Clin Microbiol Infect. 2021; 27 (7): 1041.e1–1041.e4. DOI: 10.1016/j.cmi.2021.03.012

6. Sulewski A, Sieroń D, Szyluk K, Dąbrowski M, Kubaszewski Ł, Lukoszek D, Christe A. Avascular Necrosis Bone Complication after Active COVID-19 Infection: Preliminary Results. Medicina (Kaunas). 2021 Nov 30; 57 (12): 1311. DOI: 10.3390/medicina57121311

7. Baimukhamedov C, Botabekova A, Lessova Z. et al. Osteonecrosis amid the COVID-19 pandemic. Rheumatol Int. 2023; 43 (7): 1377–1378. DOI: 10.1007/s00296-023-05332-3

8. Hassan AAA, Khalifa AA. Femoral head avascular necrosis in COVID-19 survivors: a systematic review. Rheumatol Int. 2023 Sep; 43 (9): 1583–1595. DOI: 10.1007/s00296-023-05373-8

9. Mont MA, Pivec R, Banerjee S. et al. High-Dose Corticosteroid Use and Risk of Hip Osteonecrosis: Meta-Analysis and Systematic Literature Review. J Arthroplasty. 2015 Sep; 30 (9): 1506–1512.e5. DOI: 10.1016/j.arth.2015.03.036

10. Zhao R, Wang H, Wang X, Feng F. Steroid therapy and the risk of osteonecrosis in SARS patients: a dose-response meta-analysis. Osteoporos Int. 2017; 28 (3): 1027–1034. DOI: 10.1007/s00198-016-3824-z

11. Chang C, Greenspan A, Gershwin ME. The pathogenesis, diagnosis and clinical manifestations of steroid-induced osteonecrosis. J Autoimmun. 2020 Jun; 110: 102460. DOI: 10.1016/j.jaut.2020.102460

12. Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020; 395 (10223): 497–506. DOI: 10.1016/S0140–6736(20)30183-5

13. Liu J, Li S, Liang B. et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020 May; 55: 102763. DOI: 10.1016/j.ebiom.2020.102763

14. Salvio G, Gianfelice C, Firmani F. et al. Bone metabolism in SARS-CoV-2 disease: possible osteoimmunology and gender implications. Clin Rev Bone Miner Metab. 2020; 18 (4): 51–57. DOI: 10.1007/s12018-020-09274-3

15. Zhang B, Zhang S. Corticosteroid-Induced Osteonecrosis in COVID-19: A Call for Caution. J Bone Miner Res. 2020; 35 (9): 1828–1829. DOI: 10.1002/jbmr.4136

16. Bejoy P, Prerona M, Yuti K. et al. COVID-19 and Its Long-Term Impact on the Cardiovascular System. Expert Rev. Cardiovasc. Ther. 2023; 21: 211–218. DOI: 10.1080/14779072.2023.2184800

17. Ingul CB, Grimsmo J, Mecinaj A. et al. Cardiac dysfunction and arrhythmias 3 months after hospitalization for COVID-19. J Am Heart Assoc. 2022; 11 (3): e023473. DOI: 10.1161/JAHA.121.023473

18. Bisaccia G, Ricci F, Recce V. et al. Post-acute sequelae of COVID-19 and cardiovascular autonomic dysfunction: what do we know? J Cardiovasc Dev Dis. 2021; 8 (11): 156. DOI: 10.3390/jcdd8110156

19. Soewono KY, Raney KC, Sidhu MS. Pericarditis with pericardial effusion as a delayed complication of COVID-19. Proc (Bayl Univ Med Cent). 2021; 34 (5): 629–630. DOI: 10.1080/08998280.2021.1918975

20. Dini FL, Baldini U, Bytyçi I, et al. Acute pericarditis as a major clinical manifestation of long COVID-19 syndrome. Int J Cardiol. 2023 Mar 1; 374: 129–134. DOI: 10.1016/j.ijcard.2022.12.019

21. Puntmann VO, Carerj ML, Wieters I. et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered from Coronavirus Disease 2019 (COVID-19) JAMA Cardiol. 2020; 5: 1265–1273. DOI: 10.1001/jamacardio.2020.3557

22. Moody WE, Liu B, Mahmoud-Elsayed HM. et al. Persisting Adverse Ventricular Remodeling in COVID-19 Survivors: A Longitudinal Echocardiographic Study. J. Am. Soc. Echocardiogr. 2021; 34: 562–566. DOI: 10.1016/j.echo.2021.01.020

23. Alkodaymi MS, Omrani OA, Fawzy NA. et al. Prevalence of Post-Acute COVID-19 Syndrome Symptoms at Different Follow-up Periods: A Systematic Review and Meta-Analysis. Clin. Microbiol. Infect. 2022; 28: 657–666. DOI: 10.1016/j.cmi.2022.01.014

24. Al-Khadra Y, Darmoch F, Moussa Pacha H. et al. P5341 Autoimmune disease association with pericar dial diseases: An analysis of the national inpatient sample. Eur Heart J. 2018; 39 (Suppl 1): ehy566.P5341. DOI: 10.1093/eurheartj/ehy566.P5341

25. Белов Б. С., Тарасова Г. М. Перикардиты в ревматологии: современные клинико-диагностические аспекты и вопросы терапии. Consilium Medicum. 2020; 22 (1): 26–30. DOI: 10.26442/20751753.2020.1.200060

26. Джузенова Б. С., Котельникова Г. П., Михайлова И. Н., Насонова В. А. Острый ревмокардит у молодых мужчин. Терапевтический архив. 1992; 4: 58–62.

27. Медынцева Л. Г. Физическая работоспособность больных ревматизмом детей на этапе диспансеризации: автореф. дис. канд. мед. наук. М., 1990.

28. Long Q, Li J, Hu X. et al. Follow-Ups on Persistent Symptoms and Pulmonary Function Among Post-Acute COVID-19 Patients: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2021; 8: 702635. DOI: 10.3389/fmed.2021.702635

29. Cares-Marambio K, Montenegro-Jiménez Y. et al. Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Chron Respir Dis. 2021; 18: 14799731211002240. DOI: 10.1177/14799731211002240

30. Dani M, Dirksen A, Taraborrelli P. et al. Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. Clin med (Lond). 2021; 21 (1): e63–e67. DOI: 10.7861/clinmed.2020–0896

31. Duong-Quy S, Vo-Pham-Minh T, Tran-Xuan Q. et al. Post-COVID-19 Pulmonary Fibrosis: Facts-Challenges and Futures: A Narrative Review. Pulm Ther. 2023; 9 (3): 295–307. DOI: 10.1007/s41030–023–00226-y. Epub 2023 May 20.

32. Guinto E, Gerayeli FV, Eddy RL. et al. Post-COVID-19 dyspnoea and pulmonary imaging: a systematic review and meta-analysis. Eur Respir Rev. 2023; 32 (169): 220253. DOI: 10.1183/16000617.0253-2022

33. Wu X., Liu X., Zhou Y. et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021; 9 (7): 747–754. DOI: 10.1016/S2213-2600(21)00174-0

34. George PM, Barratt SL, Condliffe R. et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020; 75: 1009–1016. DOI: 10.1136/thoraxjnl-2020-215314

35. Методические рекомендации «Особенности течения long-COVID-инфекции. Терапевтические и реабилитационные мероприятия». Терапия. 2022; 1 (Приложение): 1–147. https://dx.doi.org/10.18565/therapy.2022.1suppl.1-147

36. Recalcati S. Кожные проявления при COVID-19: первая точка зрения. J Eur Acad Dermatol Venereol. 2020; 34 (5): e212–e213. DOI: 10.1111/jdv.16387

37. Desai AD, Lavelle M, Boursiquot BC, Wan EY. Long-term complications of COVID-19. Am J Physiol Cell Physiol. 2022; 322 (1): C 1–C 11. DOI: 10.1152/ajpcell.00375.2021

38. McGonagle D, Bridgewood C, Ramanan AV, et al. COVID-19 vasculitis and novel vasculitis mimics. Lancet Rheumatol. 2021; 3 (3): e224–e233. DOI: 10.1016/S2665-9913(20)30420-3

39. Rocha KO, Zanuncio VV, Freitas BAC, Lima LM. «COVID toes»: A meta-analysis of case and observational studies on clinical, histopathological, and laboratory findings. Pediatr Dermatol. 2021; 38 (5): 1143–1149. DOI: 10.1111/pde.14805

40. Mehta P, Bunker CB, Ciurtin C. et al. Chilblain-like acral lesions in long COVID-19: management and implications for understanding microangiopathy. Lancet Infect Dis. 2021; 21 (7): 912. DOI: 10.1016/S1473-3099(21)00133-X

41. Chaudhary H, Mohan M, Jain A. et al. Acral Gangrene: Ugly Cousin of «COVID Toes» in Multisystem Inflammatory Syndrome in Children Associated with SARS-CoV-2? Pediatr Infect Dis J. 2021; 40 (8): e312–e313. DOI: 10.1097/INF.0000000000003181

42. Casas G, Català A, Hernández C. et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020; 183 (1): 71–77. DOI: 10.1111/bjd.19163

43. Perna A, Passiatore M, Massaro A. et al. Skin manifestations in COVID-19 patients, state of the art. A systematic review. Int J Dermatol. 2021; 60 (5): 547–553. DOI: 10.1111/ijd.15414

44. McMahon DE, Gallman AE, Hruza GJ. et al. Long COVID in the skin: a registry analysis of COVID-19 dermatological duration. Lancet Infect Dis. 2021; 21 (3): 313–314. DOI: 10.1016/S1473-3099(20)30986-5

45. Chularojanamontri L, Tuchinda P, Rujitharanawong C. et al. New-onset and exacerbated skin diseases after COVID-19 infection: a systematic review. J Dermatol. 2022; 49 (11): e419–e421. DOI: 10.1111/1346-8138.16501

46. Shanshal M. COVID-19 related anagen effluvium. J Dermatolog Treat. 2022; 33 (2): 1114–1115. DOI: 10.1080/09546634.2020.1792400

47. Aksoy H, Yıldırım UM, Ergen P, Gürel MS. COVID-19 induced telogen effluvium. Dermatol Ther. 2021; 34 (6): e15175–e15175. DOI: 10.1111/dth.15175

48. Wambier CG, Vaño-Galván S, McCoy J., et al. Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: the «Gabrin sign». J Am Acad Dermatol. 2020; 83 (2): 680–682. DOI: 10.1016/j.jaad.2020.05.079